• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Enhanced Influenza VLP Vaccines Comprising Matrix-2 Ectodomain and Nucleoprotein Epitopes Protects mice from Lethal Challenge

tetano

Editor, Senior Moderator
Antiviral Res. 2013 Feb 14. pii: S0166-3542(13)00027-2. doi: 10.1016/j.antiviral.2013.01.010. [Epub ahead of print]
Enhanced Influenza VLP Vaccines Comprising Matrix-2 Ectodomain and Nucleoprotein Epitopes Protects mice from Lethal Challenge.
Gao X, Wang W, Li Y, Zhang S, Duan Y, Xing L, Zhao Z, Zhang P, Li Z, Li R, Wang X, Yang P.
Source

Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, 100071,China.
Abstract

The matrix protein 2ectodomain (M2e) of the influenza A virus is a rational target antigen candidate for the development of a universal influenza virus-like particle (VLP) vaccine. In this study, a recombinant M2 protein with three tandem copies of M2e (3M2e), nucleoprotein (NP) epitopes and hepatitis B virus core (HBc), were expressed in E. coli and purified by column chromatography. Mice immunized with 3M2e-NP-HBc in combination with an oil-in-water SP01 adjuvant produced robust M2e specific antibodies and cellular immune responses. Most importantly, the 3M2e-NP-HBc VLP vaccine provided enhanced protection against a lethal challenge with pandemic 2009 H1N1 and HPAI H5N1 virus through increased survival rates, a significant decrease in viral replication, and obvious alleviation of histopathological lung changes in challenged mice. Our results imply that a cellular immune response to NP is a plausible mechanism mediating this enhanced protection. These findings suggest that 3M2e-NP-HBc VLP has great potential as the basis development of a broadly protective influenza vaccine.

Copyright ? 2013. Published by Elsevier B.V.

PMID:
23416215
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23416215
 
Back
Top Bottom